Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma
Low-grade gliomas (LGGs) are slow-growing tumors in the central nervous system (CNS). Patients characteristically show the onset of seizures or neurological deficits due to the predominant LGG location in high-functional brain areas. As a molecular hallmark, LGGs display mutations in the isocitrate...
Main Authors: | Marco Gallus, Darwin Kwok, Senthilnath Lakshmanachetty, Akane Yamamichi, Hideho Okada |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/14/3726 |
Similar Items
-
The Correlation of In Vivo MR Spectroscopy and Ex Vivo 2-Hydroxyglutarate Concentration for the Prediction of Isocitrate Dehydrogenase Mutation Status in Diffuse Glioma
by: Bart R. J. van Dijken, et al.
Published: (2023-08-01) -
Preclinical Models of Low-Grade Gliomas
by: Pushan Dasgupta, et al.
Published: (2023-01-01) -
Epigenetic Reprogramming for Targeting <i>IDH</i>-Mutant Malignant Gliomas
by: Jong-Whi Park, et al.
Published: (2019-10-01) -
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
by: Xueyuan Sun, et al.
Published: (2021-05-01) -
Vorasidenib in IDH1/2-mutant low-grade glioma: the grey zone of patient’s selection
by: Lidia Gatto, et al.
Published: (2024-01-01)